Patents Examined by Jonathan S Lau
  • Patent number: 11911406
    Abstract: Provided herein are polymer-drug conjugates with enhanced antibacterial efficacy. These conjugates include a polymer comprising a plurality of masked cationic functional groups and an antibiotic drug linked to the cationic polymer by a pH-sensitive linker. The masked cationic functional groups may be converted in aqueous solution to free cationic functional groups faster at a pH below 7 than a pH above 7. The cationic functional groups may be masked as either an uncharged functional group or by an ion pair with a neighboring anionic functional group attached to the polymer. The pH-sensitive linker releases the drug faster in aqueous solution at or below a pre-determined pH value selected from a range of 4.5 to 7 than a pH value above 7.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: February 27, 2024
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Shaoqin Gong, Mingzhou Ye
  • Patent number: 11912734
    Abstract: A strategy using reverse phosphoramidites for synthesizing oligonucleotides containing Fapy·dG is disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: February 27, 2024
    Inventors: Marc M. Greenberg, Haozhe Yang
  • Patent number: 11911412
    Abstract: Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: February 27, 2024
    Assignee: SYNEDGEN, INC.
    Inventors: Shenda M. Baker, William P. Wiesmann
  • Patent number: 11903956
    Abstract: Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 20, 2024
    Inventor: Huiru Wang
  • Patent number: 11903957
    Abstract: A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A ?1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 20, 2024
    Inventors: Mi Young Lee, Yu Ri Kim, Young Hwa Kim, Bo-Kyung Park
  • Patent number: 11897914
    Abstract: Embodiments of the present application relate to the preparation of 2?-O-protected nucleoside phosphoramidites and conjugation of the 2?-O-protected nucleoside to a solid support. More specifically, the present application relates to nucleosides having a hydroxy protecting group at the 2? position that reduces migration to the 3? position during RNA (e.g., mRNA) synthesis and can be readily removed under mild conditions without the use of toxic metal-containing reagents. Methods of using the nucleosides described herein in RNA synthesis are also disclosed.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: February 13, 2024
    Assignee: Hongene Biotech Corporation
    Inventors: Wing C. Poon, Ruiming Zou, Aldrich N. K. Lau, David Yu, Gengyu Du, Yun-Chiao Yao, Gang Zhao
  • Patent number: 11891413
    Abstract: The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—Ux+4—Ux+3—Ux+2—Ux+1—Ux)m—(Vx+2—Vx+1—Vx)1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 6, 2024
    Inventors: Arun Naini, Daniel Knopp, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
  • Patent number: 11884753
    Abstract: A compound having Formula (I) or Formula (II): or a mixture thereof, in which R is —H; —CH3; —CH—(CH3)2; —CH2—CH—(CH3)2; —CH—(CH3)—CH2—CH3; —CH2—(C6H5); —CH2—(3-indole); —CH2—CH2—S—CH3; —CH2—OH; —CH—(CH3)—OH; —CH2—SH; —CH2-(p-C6H4OH); —CH2—CH2—CH2—CH2—NH2; —CH2—CO—NH2; —CH2—CH2—CO—NH2; —CH2—CH2—COOH; —CH2—COOH; or —CH2—CH2—NH—C?NH2(NH2); and X is a suitable non-interfering anion, a process for making the compound having Formula (I) or Formula (II), and a process for reacting the compound having Formula (I) or Formula (II) or a mixture thereof with a (poly)saccharide to form a cationized (poly)saccharide.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: January 30, 2024
    Assignee: SACHEM, INC.
    Inventor: Tim Engel
  • Patent number: 11883406
    Abstract: The present invention relates to a method for producing an alginic acid-folic acid conjugate, an alginic acid-folic acid conjugate produced thereby, and a pharmaceutical composition containing the same. According to the method of producing an alginic acid-folic acid conjugate using a carboxy-protecting group and a leaving group, the hydroxyl group of alginic acid forms an ester group with the carboxyl group of folic acid. Thus, the alginic acid-folic acid conjugate may clearly distinguish cancer cells from normal tissue by more effectively targeting cancer cells than a conventional alginic acid-conjugated folic acid in which the amine group of folic acid is covalently bonded to the carboxyl group of alginic acid. Accordingly, the alginic acid-folic acid conjugate may be effectively used for precise diagnosis and efficient surgical resection of cancer lesions.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: January 30, 2024
    Inventors: Kang Won Lee, Sa Ra Lee
  • Patent number: 11859023
    Abstract: Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex. In certain aspects, the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking. In certain aspects, the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran. In exemplary implementations, the functionalized dextran is an amine dextran. In further embodiments, one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: January 2, 2024
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventors: Jeffrey Arnold, David A. Ralph
  • Patent number: 11826378
    Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: November 28, 2023
    Inventors: Carla Kroh, Ingo Ulrich Lang, Horst Rose, Franziska Roessner, Saskia Kley
  • Patent number: 11819498
    Abstract: The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: November 21, 2023
    Inventors: Vojo P. Deretic, Jia Cassano, Bhawana Bissa
  • Patent number: 11813278
    Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 14, 2023
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Patent number: 11806358
    Abstract: Methods of treating trypanosomiasis and, particularly, methods of treating trypanosomiasis using neohesperidin dihydrochalcone. Such methods of treatment are useful in, for example, animals selected from the group consisting of cattle, sheep, pigs, goats, horses, and camels.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: November 7, 2023
    Inventor: Mahmoud Kandeel
  • Patent number: 11786523
    Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: October 17, 2023
    Inventors: Lan Huang, Ramon Mohanlal, George Kenneth Lloyd
  • Patent number: 11780937
    Abstract: Provided herein is a method for extracting polysaccharides, for example, ?-glucan and sodium alginate, from a sample including a botanical product. The extraction can be carried out using a microwave assisted dual-solvent extraction followed by one or more membrane filtration steps.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: October 10, 2023
    Assignee: Nano and Advanced Materials Institute Limited
    Inventors: Chun Hay Ko, Chun Fai Ng, Ying Ying Ng, Simon Hoi Pang Sung, Zack Chun Fai Wong
  • Patent number: 11771714
    Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: October 3, 2023
    Inventors: Ralph P. Stone, Timothy R. Willis
  • Patent number: 11773127
    Abstract: The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 3, 2023
    Assignee: Washington University
    Inventors: Vasilios Kalas, James W. Janetka, Scott Hultgren, Jerry Pinkner, Amarendar Maddirala, Vishnu Damalanka
  • Patent number: 11767371
    Abstract: There is provided a method for efficiently produce hydroxypropyl methyl cellulose acetate succinate (HPMCAS) having excellent flowability, where acetic acid in a reaction product mixture subjected to a wash and recovery step can be reduced. More specifically, there is provided a method for producing HPMCAS including an esterification step of esterifying hydroxypropyl methyl cellulose (HPMC) with acetic anhydride and succinic anhydride in acetic acid as a solvent to obtain a reaction product solution containing HPMCAS; a water addition step of adding water to the reaction product solution to obtain a water-added reaction product solution; an acetic acid removal step of removing at least a portion of both the solvent acetic acid and acetic acid derived from the acetic anhydride from the water-added reaction product solution to obtain a mixture having an acetic acid content reduced; and a wash and recovery step of washing the mixture and recovering the HPMCAS.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: September 26, 2023
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Akiko Miki, Taishi Kitaguchi, Akira Kitamura, Mitsuo Narita
  • Patent number: 11752165
    Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: September 12, 2023
    Assignee: US NANO FOOD & DRUG, INC
    Inventors: Hing Sang Pui, Yip Shu Pui, Yip Ching Pui